441285-17-2

Usage

Uses

Used in Pharmaceutical Research:
2-(3-(benzyloxycarbonyl)phenyl)acetic acid is used as a key intermediate in the synthesis of various pharmaceuticals for [application reason]. Its Boc protecting group allows for selective reactions and the synthesis of complex drug molecules with specific properties.
Used in Agrochemical Development:
In the agrochemical industry, 2-(3-(benzyloxycarbonyl)phenyl)acetic acid is used as a building block for the development of new agrochemicals for [application reason]. Its reactivity and structural flexibility enable the creation of molecules with targeted biological activities, such as herbicidal, insecticidal, or fungicidal properties.
Used in Organic Synthesis:
2-(3-(benzyloxycarbonyl)phenyl)acetic acid is used as a versatile building block in organic synthesis for [application reason]. Its Boc protecting group allows for selective reactions, enabling the synthesis of complex organic molecules with specific functional groups and properties.
Note: The specific application reasons for each use case are not provided in the materials. You can fill in the appropriate reasons based on the intended application or the properties of the compound.

Upstream product

• 14338-36-4 3-amino phenylacetic acid 
• 501-53-1 benzyl chloroformate 
• 1038932-61-4 methyl N-((benzyloxycarbonyl-3-amino)-2-phenyl)acetate 
• 52273-79-7 (3-amino-phenyl)-acetic acid ethyl ester 
• 1190391-39-9 ethyl (3-{[(benzyloxy)carbonyl]amino}phenyl)acetate 

Downstream Products

• 1190391-40-2 benzyl (3-{2-[methoxy(methyl)amino]-2-oxoethyl}phenyl)carbamate 
• 1190391-38-8 benzyl [3-(2-oxobut-3-en-1-yl)phenyl]carbamate 
• 1190391-55-9 benzyl {4-[(3E,5R,6R)-5-{[(benzyloxy)carbonyl]amino}-6-{[tert-butyl(dimethyl)silyl]oxy}-6-(3-chlorophenyl)-2-oxohex-3-en-1-yl]phenyl}carbamate 
• 419573-60-7 1-N-[3-(benzyloxycarbonylamino)phenylethanoyl]-6-O-[2-N-[4-(benzyloxycarbonyl)butylamino]ethylamino]-3,2',6'-tris(N-benzyloxycarbonyl)neamine 
• 419573-58-3 N-[3-(benzyloxycarbonylamino)phenylethanoloxy]succinimide 

Relevant academic research and scientific papers

NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Synthesis and evaluation of novel aromatic substrates and competitive inhibitors of GABA aminotransferase

The design, synthesis, and evaluation of novel γ-aminobutyric acid aminotransferase (GABA-AT) inhibitors and inactivators can lead to the discovery of new GABA-related therapeutics. To this end, a series of aromatic amino acid compounds was synthesized to aid in the design of new inhibitors and inactivators of GABA-AT. All compounds were tested as competitive inhibitors of GABA-AT. The amino acids with benzylic amines were also tested as substrates for GABA-AT. It was found that these compounds were all poor competitive inhibitors of GABA-AT, but some were substrates of the enzyme, suggesting their utility as scaffolds for potential GABA-AT mechanism-based inactivators. Computer modeling was used to rationalize the substrate activity of the various compounds.

Design of novel antibiotics that bind to the ribosomal acyltransfer site

The structure of neamine bound to the A site of the bacterial ribosomal RNA was used in the design of novel aminoglycosides. The design took into account stereo and electronic contributions to interactions between RNA and aminoglycosides, as well as a ran